Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease

Kidney International

Volumn 73, Issue 5, 2008, Pages 528-530

  Auerbach, M ^a   Al Talib, K ^b  

^a Auerbach Hematology and Oncology   (United States)

^b Franklin Square Hospital Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; COSMOFER; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; IRON DEXTRAN; IRON SALT; METHYLPREDNISOLONE; UNCLASSIFIED DRUG;

ALBUMINURIA; ANAPHYLAXIS; ARTHRALGIA; CHRONIC KIDNEY DISEASE; DRUG SAFETY; HEMODIALYSIS PATIENT; HUMAN; MEDICAL LITERATURE; MYALGIA; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEINURIA; SINGLE DRUG DOSE; SUBSTITUTION THERAPY;

EID: 39349106653     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002779     Document Type: Note

References (27)

1. Feldman HI, Joffe M, Robinson B et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623-1632.
2. Kalanter-Zadeh K, Regidor DL, McAllister CJ et al. Time dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080.
3. Blaustein DA, Schwenk MH, Chattopadhyay J, Avram MM. Recent experience with high-dose intravenous iron administration. Kidney Int 2006; 70: S26-S29.
4. Vikrant S. Optimum dosage regimen for iron sucrose. Kidney Int 2007; 72: 225.
5. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001; 38: 988-991.
6. Auerbach M, Witt D, Toler W et al. Clinical use of the total dose infusion of iron dextran. J Lab Clin Med 1988; 111: 566-570.
7. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anemia. Lancet 2007; 369: 1502-1504.
8. Case G. Maintaining iron balance with total-dose infusion of iron dextran. ANNA J 1998; 25: 65-68.
9. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378-382.
10. Silverstein SB, Rodger GM. Parenteral iron therapy options. Am J Hematol 2004; 76: 74-78.
11. Mamula P, Piccoli DA, Peck SN et al. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 34: 286-290.
12. Coyne DW, Adkinson FN Jr., Nissenson AR et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextransensitive and dextran-tolerant patients. Kidney Int 2003; 63: 217-224.
13. McCarthy JT, Regnier CE, Leobertmann CL, Bergstralh EJ. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran: a comparison of two products. Am J Nephrol 2000; 20: 455-462.
14. Fletes R, Lazarus JM, Gage J, Chertow JM. Suspected iron dextran related adverse events in hemodialysis patients. Am J Kidney Dis 2001; 37: 743-749.
15. Auerbach M, Rodgers GM. Intravenous iron. N Engl J Med 2007; 357: 93-94.
16. Auerbach M, Winchester J, Wahab A et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis 1998; 31: 81-86.
17. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label randomized trial. J Clin Oncol 2004; 22: 1301-1307.
18. Auerbach M, Chaudhry M, Goldman H, Ballard H. Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. J Lab Clin Med 1998; 131: 257-260.
19. Moniem KA, Bhandari S. Tolerability and efficacy of parenteral iron therapy in haemodialysis patients: a comparison of preparations. Transfusion Altern Transfusion Med 2007; 9: 37-42.
20. Critchley J, Dundar Y. Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review. Transfusion Altern Transfusion Med 2007; 9: 8-36.
21. Sav T, Tokgoz B, Sipahioglu MH. Is there a difference between allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail 2007; 29: 423-426.
22. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103.
23. Pai AB, Boyd AV, McQuade CR et al. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 2007; 27: 343-350.
24. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2289.
25. Zager RA, Johnson AC, Hanson SW. Parenteral iron exacerbates experimental sepsis. Kidney Int 2004; 65: 2108-2112.
26. Zager RA, Johnson AC, Hanson SW, Lund S. Parenteral iron compounds sensitize mice to injury-initiated TNF alpha release. Am J Physiol Renal Physiol 2005; 288: F295-F297.
27. Agarwal R, Rizkala AR, Kaskas MO et al. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int 2007; 72: 638-642.